Announcement PDF ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 18 November 2025 Companies Announcements Office Australian Securi<es Exchange 2025 Annual General Mee.ng – CEO’s Presenta.on ImpediMed Limited (ImpediMed) (ASX:IPD) provides the a9ached CEO’s presenta@on to be delivered at today’s Annual General Mee@ng commencing at 11.00am AEDT. Approved for release by the Board of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au 1 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. Forging New Standards of Care 2 Forward Looking Statements Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited). Video Overview SOZO® Market Opportunity BCRL Update Cardiometabolic Business Financials Strategy for the Next Year 2025 AGM CEO Presentation AGENDA 4 SOZO® Digital Health Platform with Multiple FDA Cleared Applications A single SOZO measurement provides: • L-Dex® lymphoedema analysis • HF-Dex® heart failure analysis • Body CompTM • Hy-Dex® hydration analysis One device, multiple FDA cleared applications Lymphoedema ✓ FDA clearance ✓ CE Mark ✓ TGA clearance Body composition ✓ FDA clearance ✓ CE Mark ✓ TGA clearance Heart failure ✓ FDA clearance ✓ CE Mark ✓ TGA clearance Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Expanding SOZO® to Growing US Patient Populations 5 Obesity Sarcopenia Unmanaged Weight Loss Heart Failure $1.1b TAM 6m Patients Lymphoedema $600m TAM 4m Breast Cancer Survivors1 Weight Management $650m TAM 13m US patients on GLP-1s2 Cardiometabolic Health Outcomes Cancer Survivorship Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. SOZO Workflow fits into current clinical workflow to extend from cancer survivorship into cardiometabolic health 6 Patient visits their local clinic or hospital Patient enters the exam room and steps on the SOZO MA reviews clinical data and SOZO measurement SOZO data sent digitally through EHR integration Clinician reviews and adjusts treatment plan Encounter billed as per relevant CPT code Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 7 Cancer Survivorship | Prevention of Breast Cancer Related Lymphoedema BIS in updated NAPBC Standards Multiple Guidelines and Standards Support Early Detection NCCN FDA cleared PREVENT trial: n=1,200 10 US and international centers including Vanderbilt University, Mayo Clinic and MD Anderson Tape measure (23/100) L-Dex (7/89) 19.2% 7.9% p=0.016 Absolute reduction: 11.3% Relative reduction: 59% Positive Global Clinical Trial 1200 patient trial: Statistically Significant Lower Progression to Chronic Lymphoedema1 1,100+ devices deployed globally $600m BCRL TAM 1.2m patient tests conducted World-leading Hospitals Deployed in 18 of Top 25 US Hospitals2 1. Published in Lymphatic Research & Biology https://www.liebertpub.com/doi/10.1089/lrb.2021.0084 2. https://rankings.newsweek.com/worlds-best-hospitals-2025/united-states-america Increasing Depth of US Payor Coverage Year on Year Comparison 2024 AGM 2025 AGM Increase US Payor Coverage 73% 87% Covered Lives (million) 255 304 19% Number of US States > 80% coverage 23 41 78% Number of US States > 90% coverage 7 26 271% Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Cardiometabolic health | Improving Outcomes and Quality of Life for Patients living with Heart Failure 8 The Heart Failure Opportunity ✓ FDA clearance ✓ CIED cleared SOZO® Pro device ✓ Financially sustainable for providers with a CPT code ✓ Heart Failure Clinical data generated US controlled market release underway ✓ Targeting 11 high reimbursement, high population states ✓ IIR studies at 2 sites ✓ Launch underway 1. Bahira Shahim Global Public Health Burden of Heart Failure: An Updated Review; Card Fail Rev. 2023 Jul 27;9:e11. doi: 10.15420/cfr.2023.05 2. Atherton, J.J., Sindone A, De Pasquale CG, et al., National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ, 2018. 27(10): p. 1123-1208. 3. Dharmarajan, K., et al., Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013. 309(4): p. 355-63. 4. Khan et al Trends in 30- and 90-Day Readmission Rates for Heart Failure Circulation: Heart Failure Volume 14, Number 4Int J Cardiol. 2017 June 01; 236: 283–289. doi:10.1016/j.ijcard.2017.01.153.. 5. Denfield et al. The Prevalence of Frailty in Heart Failure: A Systematic Review and Meta-Analysis. Int J Cardiol. 2017 Feb 10;236:283–289. doi: 10.1016/j.ijcard.2017.01.153 6. Shen et al Understanding Obesity-Related High Output Heart Failure and Its Implication Int J Heart Fail. 2021 Jan 13;3(3):160–171. doi: 10.36628/ijhf.2020.0047 7. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or over Total US medical costs for HF are projected to increase to $70b by 2030, 2x increase from 2013 Improving Outcomes and QOL for Patients Living with Heart Failure with financially sustainable solution for Providers Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. SOZO® Pro For Cardiology Patients 9 Fluid Status Monitoring to Guide Treatment​ • HF-Dex offers a sensitive index of fluid status, more than twice as sensitive as weight monitoring for fluid changes (n=69, p<0.0001)1 • HF-Dex values over 51% post-discharge indicate a four- fold higher risk of readmission, helping prioritize follow- up care (n=89, p=0.04)2 • Distinguishes between fluid status in individuals with and without heart failure with 80% sensitivity and specificity.3 Comprehensive Body Composition Tracking​ • SOZO tracks fat, fat-free mass, and skeletal muscle to support personalized rehabilitation and weight management.​ Integrates into existing nurse-led clinical workflows​ • 30 second test which replaces the scale in existing workflows with EHR integration (incoming feature) • Able to be used on patients with implantable devices • Transport friendly design • CPT code 93701 coverage 1. Burns et al Time-to-Decongestion Following HeartFailure Hospitalization as Measured by Extracellular Fluid Nadir Using Bioimpedance Spectroscopy. Poster & Abstract:HSFA Annual Scientific Meeting, 2021​ 2. Burns et al Bioimpedance Spectroscopy Measurement of Ongoing Fluid Overload Post-Discharge from Hospitalization for Decompensated Heart Failure. Poster and Abstract: HSFA Annual Scientific Meeting, 2022 J Card Fail. 2023;29(4):656-7​ 3. Accardi etal Bioimpedance Spectroscopy Distinguishes Between Fluid Status in Individuals with and without Heart Failure;J Card Fail. 2023;29(4):656-7​ Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. SOZO® Pro for Cardiology Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 10 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Raising the Bar in an Accelerating Weight Management Market 11 Raising the Bar with BIS: Precision Body Composition with One Scan ✓ Large and Growing Market “ Global MedSpa market expected to grow from US $18Billion to $US72 Billion next few years"1 ✓ GLP-1 driven growth “Over 13M users in US, 790,000 prescribers, women, aged 50 - 64 use at higher rates”2 ✓ Guidelines to move beyond BMI “From Lancet, Obesity Society3” ✓ FDA-Cleared in healthy & unhealthy populations ✓ Leverage off BCRL and existing/overlapping body comp clinical customer base ✓ Sales in progress ✓ Updating messaging and imaging ✓ Dedicated sales team 1. MedSpa Pro Conference 2. https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies 3. Mozzafarian etal.Nutritional priorities to support GLP-1 therapy for obesity: a Joint Advisory from the American College of Lifestyle Medicine,the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition Volume 122, Issue 1, July 2025, Pages 344-367 4. The Obesity Society Applauds the Work ofThe LancetDiabetes & Endocrinology Commission on Diagnostic Criteria ofClinical Obesity. The Obesity Society. January 2025 @ Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. SOZO® Pro for Medically Managed Weight Change 12 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 13 1. SOZO CoreBusiness represents revenue from SOZO contracts in the Oncology/Lymphoedema market and excludes SOZO clinical business and legacy device/other revenues. Core Business Revenue and ARR improving Total revenue $12.7 million 23% vs FY24 SOZO Core Business1 revenue $12.1 million 25% vs FY24 SOZO Core Business ARR $14.0 million 27% vs FY24 Gross profit margin 86% 1% vs FY24 Cash balance at close of FY25 $22.2 million Number of patient tests conducted 287,000 15% vs FY24 FY25 Full-Year Results SOZO Core Business TCV $19.2 million 100% vs FY24 # SOZO units sold globally 114 68% vs FY24 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. SOZO Core Business Revenue and ARR continues to grow 14 1. Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The amounts shown are as reported. The exchange rate used for FY25 H2 ARR calculation was 0.6434 (2024: 0.6670). 2. Compound Annual Growth Rate. SOZO Core Business ARR1 A$ millions ARR up 27% vs. FY24 ($11.0m) 24% 3-year CAGR2 SOZO Core Business Revenue FY25 SOZO Core Business revenue up 25% vs. FY24 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Momentum Continues | Forward sales indicators improve and TCV momentum returns 15 U.S. SOZO Units Sales Pipeline1 1.Total Opportunity Pipeline represents SOZO units in pipeline at end of quarter. Q4 FY25 Pipeline up 60% vs. Q4 FY24 SOZO Core Business Quarterly TCV Record quarterly increase in TCV2 2. Total Contracted Value (TCV) relates to new and renewed contracts and includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years. Sales Pipeline up 60% Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Patient testing up 15% vs. FY24 and 21% 3-year CAGR 16 1.Compound Annual Growth Rate (based on annual totals). SOZO Patient Test’s (000s) 15% growth vs. FY24 21% 3-year CAGR An important driver of renewals 21% 3-year CAGR1 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Drive long term sustainable growth in the business 17 BCRL sales execution World-class customer experience Rest of World Expansion Progress to break even Cardiometabolic Health expansion • Pipeline conversion • Expand on 27 MSAs • Target 100% payor coverage • Medically managed weight change and wellness • Heart Failure US controlled market launch Ensure everything we do is underpinned by quality and integrity • Reduce cash burn • Process automation Next 12 months: Execute towards profitability GOAL 1 GOAL 2 GOAL 5 GOAL 3 GOAL 4 July 2026 12-Month Priorities • Keep Churn <3% • Leverage AI to create scalable and cost-effective processes Focus for the Next Year • Expansion of ROW and shift to SaaS model Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. AI to drive operational efficiencies and improve customer experience Software Development • Unit Test Coverage We are adopting Claude Code to generate new unit tests and improve coverage from 30 to 80%+. • AI CodeFix and Security Rewrote our Software Development Plan to use tools like SonarQube AI to write and fix code. 18 Sales Optimization • Lead Generation Using AcuityMD data and Seamless.ai we generate more targeted sales leads. We then validate them with an Outreach.io AI platform. Customer Experience • CoPilot Knowledge Base Company-wide access to CoPilot, trained on our existing FAQ’s, SOPs and CRM data. • Support Agent Building a new Support AI Agent to triage, tag in CRM and draft replies to Customer Support emails. Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 19 The ImpediMed Value Proposition • Only FDA-cleared BIS technology • Clinically validated and included in major cancer- care guidelines. • Large market supporting cancer survivorship. • Established global footprint, installed in leading hospitals and cancer centers. • Ongoing expansion into Cardiometabolic Health. • Hardware platform allows rapid addition of new indications. • Subscription revenue model with reliable annuity revenue stream with attractive margins. • Broad Payor coverage supports provider adoption and financial sustainability. Advanced technology with unique advantage Large and growing market opportunity Strong business model Innovation and product pipeline Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. Thank You 20 Question Procedures Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 21